Latest News

Janssen speeds up guselkumab approval process

New HQ of Morphosys, which developed guselkumab, © MorphoSys AG


by tg

Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications.

Janssen Research & Development, LLC has accelerated the US market approval process of guselkumab, a human anti-IL-23 antibody licenced from MorphoSys AG, in moderate to severe plaque psoriasis. According to its partner, the Johnson & Johnson affiliate applied a priority review voucher to the guselkumab biologics license application (BLA). In case of a positive decision by the FDA, Janssen expects US approval in Q3/17.

Janssen said it will conduct  three new phase III trials with the anti-inflammatory antibody: a head-to-head efficacy study of guselkumab vs. Novartis’ anti-IL 17A antibody secukinumab (ECLIPSE study) currently enrolling patients in the indication targeted for approval; a study in psoriatic arthritis set to start in Q3/17; and a Phase III programme in Crohn's disease.

Psoriasis is a bull market with 125 million patients worldwide, 20% of which are estimated to have the moderate to severe form.




Pharming receives complete response letter from FDA

In 2017, Pharming filed an sBLA to the FDA in order to expand the label of its recombinantly produced C1 esterase inhibitor Ruconest to prophylaxis...

Boehringer Ingelheim starts gene therapy collaboration for cystic fibrosis

Under the deal, Boehringer Ingelheim acquires an option to licence IP from Imperial Innovations, the tech transfer arm of Imperial College London,...

Germany to pump €1bn into breakthrough innovation

The German agency precede EU plans to create a similar EU agency within its next research framework programme starting in 2021. The agency will be...

Phase III success for Roche breast cancer drug

Roche said the phase III study KATHERINE met its primary endpoint, showing Kadcyla (trastuzumab emtansine) as a single agent significantly reduced...

Getting ready for Brexit

Hard Brexit or soft Brexit – however the UK will leave the European Union next year, the process is sure to cause some disruption. Now, pharma...

EU approves Shire's van Willebrand factor

The European Commission granted EU approval for Veyvondi to prevent bleeding events and  surgical bleeding in desmopressin-refractive adults...

PD1/PD-L1blockers trigger metastases

A retrospective study on 377 patients with advanced non small cell lung cancer (NSCLC) who received PD-1 blockers as second-line therapy or later...